Key Abstracts From the 2020 Annual Meeting of the American Epilepsy Society

Sheryl Haut, MD


December 29, 2020

New research shows that genetic testing for adults with epilepsy can lead to the discovery of actionable mutations.

The study from Invitae is noted by Dr Sheryl Haut, professor of neurology at the Albert Einstein School of Medicine, as one of the key findings presented at AES 2020, the 74th annual meeting of the American Epilepsy Society. Researchers concluded that increased testing may help more patients gain access to precision medicine therapies, including newly diagnosed adults who suffered childhood-onset seizures.

Also in this ReCAP, Dr Haut discusses new evidence to support long-term use of add-on cannabidiol for patients with treatment-resistant epilepsies, including convulsive and nonconvulsive seizure subtypes. She highlights a post-hoc analysis of an open-label extension trial that shows repeated, intermittent use of midazolam nasal spray can help patients with seizure clusters return to full baseline functionality.

Finally, Dr Haut shares new data from the My Seizure Gauge program that ties wearable devices to improved seizure forecasting.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.